checkAd
    Startseite > Aktien > Athira Pharma > Nachrichten
    Athira Pharma Aktie
    2,6200
     
    USD
    +3,56 %
    +0,0900 USD
    Letzter Kurs 02:00:00 Nasdaq
    2,6000
     
    USD
    800 STK
    Geldkurs 31.05.24
    2,6200
     
    USD
    400 STK
    Briefkurs 31.05.24
    ISIN: US04746L1044 · WKN: A2QCFW · SYM: ATHA · USA

    Neueste Nachrichten

    Athira Pharma to Participate in Upcoming June Conferences
    29.05.24 · globenewswire · Athira Pharma
    Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
    17.05.24 · globenewswire · Athira Pharma
    Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
    15.05.24 · globenewswire · Athira Pharma
    Athira Pharma to Participate in Upcoming May Conferences
    02.05.24 · globenewswire · Athira Pharma
    Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
    15.04.24 · globenewswire · Athira Pharma
    Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
    11.04.24 · globenewswire · Athira Pharma
    Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
    03.04.24 · globenewswire · Athira Pharma
    Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD 2024 International Conference
    08.03.24 · globenewswire · Athira Pharma
    Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
    22.02.24 · globenewswire · Athira Pharma
    Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
    08.02.24 · globenewswire · Athira Pharma
    Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
    08.01.24 · globenewswire · Athira Pharma
    Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
    03.01.24 · globenewswire · Athira Pharma